Talented big men who can play across the defensive front and rush the quarterback will almost always have a place in the NFL. Given David Irving's numerous off-field troubles, though, it appears the Dallas Cowboys defensive lineman may be left behind once free agency begins next month.

In a Wednesday appearance on “Golic and Wingo,” ESPN's Adam Schefter all but guaranteed Irving won't be signed in the opening days of free agency, and allowed for the possibility that a contract offer may not materialize at all.

“David Irving, [the Cowboys] are not going to bring back,” he said, per 247 Sports' Jordan Dajani. “It seems like that's been very clear from Dallas' standpoint that they'll let him get to the market and again, when you have questions like this hanging over you, you wonder if any team is going to go sign a guy like that. They are going to wait for the process to play itself out however it does, and if he's acquitted and if there's no suspension, I'm sure there would be some team that will have some interest in signing him at that point in time, but again when we see the league year open on March 13, and negotiations begin on March 11 that Monday, there are a lot of players that are going to be signed out of the box. David Irving is not going to be in that group right now, it's just not going to happen that way with some of these questions surrounding him going forward.”

Irving was a budding star two years ago, but multiple suspensions have clouded his NFL future.

The 6-foot-7, 290-pounder had seven sacks, nine tackles for loss, and 10 quarterback hits over only eight games in 2017, missing the the season's first four games due to violating the league's performance enhancing drugs policy before being shut down for good in Week 13 after sustaining another concussion. Irving played in just two games a season ago after facing an additional suspension, this time for violating the league's substance abuse policy.

Earlier this week, reports emerged that the NFL is again investigating Irving for failing a drug test.